Gerresheimer (GXIN) Stock Price & Analysis
GXIN Stock Chart & Stats
- Day’s Range
- MXN 672.05 - MXN 672.05
- 52-Week Range
- MXN 347.84 - MXN 1,649.75
- Previous Close
- MXN 672.05
- Volume
- 0
- Average Volume (3M)
- 12
- Market Cap
- MXN 23.22B
- Enterprise Value
- MXN 3.53B
- Total Cash (Recent Filing)
- MXN 167.61M
- Total Debt (Recent Filing)
- MXN 2.21B
- Price to Earnings (P/E)
- ―
- Beta
- 0.29
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 15.65
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.13%
Bulls Say, Bears Say
Bulls Say
Steady Revenue Growth
Revenue growth across several years indicates expanding demand for Gerresheimer’s pharmaceutical packaging and delivery products. Continued top-line expansion provides a durable base for operating leverage and supports investment in specialized products, customer programs, and future capacity.
Positive Operating Cash Flow
Positive operating cash flow demonstrates that the core business continues to convert customer sales into cash despite recent profitability challenges. This underlying cash generation supports ongoing operations and provides some internal funding capacity for investment and debt servicing.
Recurring Healthcare Demand
Products used to store, protect, and administer medicines are tied to continuing pharmaceutical production rather than purely discretionary purchases. Long-term customer relationships and recurring volume demand can support business resilience and make specialized solutions harder to replace.
Bears Say
Swing To Net Loss
The shift from consistent operating profitability in 2020–2024 to substantial EBIT and net losses in 2025 is a material deterioration in earnings quality. If not reversed, weaker profitability could reduce reinvestment capacity and undermine returns from the company’s growing revenue base.
Higher Leverage
Rising debt alongside a shrinking equity base increases financial risk and reduces flexibility during an operating downturn. Greater leverage can constrain capital allocation, raise dependence on financing, and make it harder for Gerresheimer to absorb further earnings weakness.
Deeply Negative Free Cash Flow
Large negative free cash flow means positive operating cash generation is not covering investment, working-capital needs, or other cash uses. Persistent cash conversion weakness increases reliance on external financing, which is especially concerning while debt is rising and earnings are negative.
Gerresheimer News
GXIN FAQ
What was Gerresheimer’s price range in the past 12 months?
What is Gerresheimer’s market cap?
When is Gerresheimer’s upcoming earnings report date?
How were Gerresheimer’s earnings last quarter?
Is Gerresheimer overvalued?
Does Gerresheimer pay dividends?
What is Gerresheimer’s EPS estimate?
How many shares outstanding does Gerresheimer have?
What happened to Gerresheimer’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Gerresheimer?
What is the TipRanks Smart Score and how is it calculated?
Gerresheimer Stock Smart Score
Company Description
Gerresheimer
Gerresheimer AG, founded in 1864 and based in Düsseldorf, Germany, is a global supplier specializing in the production and sale of packaging solutions and sophisticated drug delivery systems. The company operates through three distinct divisions. Its Plastics & Devices segment provides a variety of drug administration tools, such as inhalers, insulin pen systems, prefillable syringes, and diagnostic systems, for the pharmaceutical, biotech, diagnostics, and medical technology sectors. This division also manufactures plastic containers, closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and related accessories for solid, liquid, and ophthalmic applications, alongside bottles for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging products for the pharmaceutical and cosmetics industries, including infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; and miniature bottles for liquid food, spices, spirits, fragrances, deodorants, skincare, and wellness products. Lastly, the Advanced Technologies division focuses on developing intelligent drug delivery systems, like micro pumps, designed to enable the self-administration of medication for conditions such as Parkinson's disease or heart failure, serving its pharmaceutical and biotech clients.
- Sector
- General
- Industry
- Medical - Instruments & Supplies
- CEO
- Uwe Ferdinand Röhrhoff
- Employees
- 13,301
- Website
- www.gerresheimer.com
- Address
- Peter-Müller-Straße 3, Düsseldorf, NW, 40468, DE
Gerresheimer (GXIN) Earnings & Revenues
GXIN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 2 | 6 |
| Technical Analysis | 2 | 2 | 4 |
| Moving Averages | 10 | 0 | 2 |








